Curse and blessing:upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome  

作　　者：Juliane Grimm Mascha Binder 

机构地区：[1]Department of Internal Medicine IN,Oncology/Hematology,University Hospital Halle(Saale),Halle(Saale),Germany

出　　处：《Signal Transduction and Targeted Therapy》2022年第9期3150-3151,共2页信号转导与靶向治疗（英文）

摘　　要：In a recently published study in The New England Journal of Medicine,Liu and colleagues were able to demonstrate that-apart from the antileukemic effects previously reported for hypomethylating agents(HMAs)-treatment with these drugs can also lead to demethylation and subsequent upregulation of oncogenes resulting in shorter survival in patients with myelo-dysplastic syndrome(MDS).

关 键 词：DRUGS myelo TREATMENT 

分 类 号：R730.5[医药卫生—肿瘤]